Drug Trial Radar · NCT05126901
Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years
Last checked: Nov 20, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
Nov 3, 2021
Primary completion
Jun 9, 2024
Study completion Jun 9, 2024
Sponsor
- Lead sponsor
- Shield TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to compare the safety and gastrointestinal tolerability of ferric maltol oral suspension and ferrous sulfate oral liquid in children and adolescents aged 2 years to 17 years, and assess the safety and tolerability of ferric maltol oral suspension in children 1 month to less than 2 years, in the treatment of iron deficiency anaemia during the 12 weeks treatment period.
Conditions
- Anemia
- Iron-deficiency
Interventions
Ferric MaltolDrug
Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to \< 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID.
Ferrous sulfateDrug
Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid : 15 ml glass bottle. Study dosage: For ferrous sulfate oral liquid, the dose administered will be for children and adolescents aged 2 years to 17 yrs: 6 mg/kg to the maximum of 4 ml BID.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Hemoglobin ConcentrationTime frame: From baseline to week 12.
Locations
23 sites in 3 countries. Site status is shown where the registry gives one.
The Center for Clinical Trials
Saraland, Alabama
Homestead Research Institute
Homestead, Florida
Kissimmee Clinical Research Corp
Kissimmee, Florida
Miami Clinical Research
Miami, Florida
Medical Research of Westcheste
Miami, Florida
Eminent Clinical Research and Associates
North Lauderdale, Florida
Clinical Research Prime
Idaho Falls, Idaho
Sierra Clinical Research
Las Vegas, Nevada
Levine Cancer Institute
Charlotte, North Carolina
Penn State Hershey Children's Hospital
Hershey, Pennsylvania
Hasbro Children's Hospital
Providence, Rhode Island
BRCR Global Texas
Edinburg, Texas
Zion Research
Katy, Texas
MultiCare Health System Institute for Research and Innovation
Tacoma, Washington
BRCR Global Puerto
San Juan, Puerto Rico
Noah's Ark Children's Hospital for Wales
Cardiff, United Kingdom
Royal Hospital for Sick Children - Edinburgh
Edinburgh, United Kingdom
Leicester Royal Infirmary
Leicester, United Kingdom
Alder Hey Children's NHS Foundation Trust
Liverpool, United Kingdom
King's College Hospital
London, United Kingdom
Newham University Hospital
London, United Kingdom
Royal Manchester Children's Hospital
Manchester, United Kingdom
Nottingham University Hospitals
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.